SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC lifted its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 21.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,953,806 shares of the company's stock after acquiring an additional 350,970 shares during the period. Silvercrest Asset Management Group LLC owned 4.66% of SI-BONE worth $27,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of SI-BONE by 4.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after buying an additional 988 shares during the period. Invesco Ltd. lifted its holdings in SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after acquiring an additional 1,413 shares during the last quarter. Rhumbline Advisers lifted its holdings in SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after acquiring an additional 1,683 shares during the last quarter. Barclays PLC grew its position in SI-BONE by 2.7% in the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock worth $1,391,000 after acquiring an additional 2,589 shares during the period. Finally, Alliancebernstein L.P. increased its stake in SI-BONE by 6.2% during the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock worth $782,000 after acquiring an additional 3,250 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

SI-BONE Stock Down 2.1%

SIBN stock traded down $0.40 during mid-day trading on Thursday, reaching $18.73. The company had a trading volume of 100,843 shares, compared to its average volume of 374,292. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The company has a market capitalization of $797.97 million, a price-to-earnings ratio of -20.41 and a beta of 0.82. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The firm has a fifty day simple moving average of $15.11 and a 200 day simple moving average of $15.14.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity at SI-BONE

In related news, CEO Laura Francis sold 5,412 shares of the business's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $19.49, for a total value of $105,479.88. Following the completion of the sale, the chief executive officer now directly owns 490,987 shares of the company's stock, valued at $9,569,336.63. The trade was a 1.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,311 shares of the company's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the transaction, the insider now owns 284,555 shares of the company's stock, valued at $4,026,453.25. This represents a 1.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 92,565 shares of company stock valued at $1,669,871 over the last three months. 4.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Truist Financial lifted their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.